

## ADVOCACY - MAKING OUR VOICES COUNT

### RESPONSE TO THE DRAFT DISABILITY STRATEGY 2026-2030



Network-wide consultation informed feedback to Whaikaha on the Draft NZ Disability Strategy 2026–2030. Chairs from the Neurodevelopmental, General Paediatric, and Child Protection Networks contributed insights supporting the strategy's foundation and identifying ways to improve outcomes for New Zealand's 98,000 disabled children. Clinician input emphasized diagnostic gatekeeping, early intervention, and workforce development.

[Read the submission here.](#)

### SUPPORT FOR PHARMAC PROPOSAL FOR ADDITIONAL ADHD MEDICATION OPTION

The [Neurodevelopment Clinical Network](#) submitted feedback supporting PHARMAC's proposal to fund Methylphenidate Sandoz XR from 1 December 2025. This additional option is expected to ease supply shortages and offer prescribers greater flexibility in ADHD management. [Read the submission here.](#)



### SUBMISSION HIGHLIGHTS GAPS IN CGM ACCESS FOR CHILDREN



[The NZ Clinical Network for Children and Young People with Diabetes](#) submitted feedback to PHARMAC supporting the removal of Special Authority renewals for five medicines. They also urged the inclusion of Continuous Glucose Monitors (CGMs), noting that excluding CGMs - despite over 18,000 eligible patients, including 2,500+ tamariki and rangatahi - risks undermining the reform's intended benefits. [Read the submission here.](#)